Profile Pharma

Profile Pharma is a UK-based pharmaceutical company and a subsidiary of the Zambon Group, specializing in the commercialization of treatments for rare and chronic diseases. The company focuses primarily on respiratory health, particularly cystic fibrosis, and central nervous system disorders such as Parkinson's disease. Their portfolio includes Promixin, an inhaled antibiotic for lung infections, and the APO-go range for managing advanced Parkinson's symptoms. Profile Pharma is known for integrating drug therapies with advanced delivery systems, such as the I-neb Adaptive Aerosol Delivery (AAD) system. Since its acquisition by Zambon in 2013, it has served as a key commercial hub for the group's specialty care products in the UK and Ireland.